Mexiletine or catheter ablation after amiodarone failure in the VANISH trial-Reference-Cited by-同舟云学术

Mexiletine or catheter ablation after amiodarone failure in the VANISH trial

Published:2018-02-01 Issue:4 Volume:29 Page:603-608
ISSN:1045-3873
Container-title:Journal of Cardiovascular Electrophysiology
language:en
Short-container-title:J Cardiovasc Electrophysiol

Author:

Deyell Marc W.¹^ORCID,Steinberg Christian²,Doucette Steve³,Parkash Ratika³,Nault Isabelle²,Gray Chris³,Essebag Vidal⁴,Gardner Martin³,Sterns Laurence D.⁵,Healey Jeff S.⁶,Hruczkowski Tomasz⁷,Rivard Lena⁸,Leong-Sit Peter⁹,Nery Pablo B.¹⁰^ORCID,Sapp John L.³

Affiliation:

1. Heart Rhythm Services, Division of Cardiology, Department of Medicine; University of British Columbia; Vancouver British Columbia Canada

2. Institut Universitaire de Cardiologie et Pneumologie de Québec; Universite Laval; Quebec City Quebec Canada

3. Department of Medicine; QEII Health Sciences Centre and Dalhousie University; Halifax Nova Scotia Canada

4. McGill University Health Centre and Hôpital Sacré-Coeur de Montréal; Montreal Quebec Canada

5. Royal Jubilee Hospital; Victoria British Columbia Canada

6. Population Health Research Institute; Hamilton Ontario Canada

7. Mazankowski Alberta Heart Institute; University of Alberta; Edmonton Alberta Canada

8. Institut de Cardiologie de Montréal; Montreal Quebec Canada

9. Heart Rhythm Service, University Hospital; Western University; London Ontario Canada

10. University of Ottawa Heart Institute; Ottawa Ontario Canada

Funder

Biosense Webster

Michael Smith Foundation for Health Research

Canadian Institutes of Health Research

St. Jude Medical

Publisher

Wiley

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jce.13431/fullpdf

Reference17 articles.

1. Sudden cardiac death in heart failure trial I: Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure;Bardy;N Engl J Med,2005

2. Inappropriate implantable cardioverter-defibrillator shocks: Incidence, predictors, and impact on mortality;Rees;J Am Coll Cardiol,2011

3. Optimal pharmacological therapy in cardioverter defibrillator patients I: Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: The OPTIC study: A randomized trial;Connolly;JAMA,2006

4. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias;Pedersen;Europace,2014

5. Long-term results after single and multiple procedures of ablation of ventricular tachycardia;Donateo;J Cardiovasc Electrophysiol,2016

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of patients with an electrical storm or clustered ventricular arrhythmias: a clinical consensus statement of the European Heart Rhythm Association of the ESC—endorsed by the Asia-Pacific Heart Rhythm Society, Heart Rhythm Society, and Latin-American Heart Rhythm Society;Europace;2024-03-30

2. Relevance of mexiletine in the era of evolving antiarrhythmic therapy of ventricular arrhythmias;Clinical Research in Cardiology;2024-02-14

3. Indications for mexiletine in the new ESC guidelines and beyond;Expert Opinion on Pharmacotherapy;2023-06-13

4. Multidisciplinary Critical Care Management of Electrical Storm;Journal of the American College of Cardiology;2023-06

5. Case 12;Clinical Cases in Cardiac Electrophysiology: Ventricular Arrhythmias;2023